Lipoprotein(a), PCSK9 Inhibition and cardiovascular risk: Insights from the Fourier trial. (August 2018) - O'Donoghue, M.; Giugliano, R.; Keech, A.; Kanevsky, E.; Im, K.; Pineda, A.Lira; Somaratne, R.; Sever, P.; Pederson, T.; Sabatine, M.